GLP-1 peptides: cure or curse?

Where each compound actually stands

The four compounds most people mean by "GLP-1" are in completely different regulatory positions, and vendors routinely present them as though they were interchangeable. They are not.

Retatrutide sits at Tier B rather than Tier A because it now has substantial controlled human trial data and no approval. That is the exact definition of the tier, and it is worth being precise about what it licenses us to say: we can report what the trials found. We cannot tell you it is safe to use, because no regulator has yet examined the full dossier and concluded that.

What retatrutide is actually being studied for

Vendors tend to present retatrutide as a weight loss compound and nothing else. The trial registry says otherwise. A search of ClinicalTrials.gov on 5 September 2026 returns 33 registered retatrutide studies, 14 of them Phase 3, and the programme reaches well beyond obesity into the conditions that travel with it.

Two things are worth drawing out of that list, and they point in opposite directions.

The first is that this is a serious, broad development programme aimed at obesity and the diseases that follow it, not a physique drug. Knee osteoarthritis, sleep apnoea, kidney disease and fatty liver are all conditions that improve when severe obesity improves, and Lilly is running the trials to find out by how much. That is a point in favour of the compound.

The second is that a registered trial is a question, not an answer. A Phase 3 study of retatrutide in chronic low back pain means somebody thought the hypothesis was worth testing. It does not mean retatrutide treats back pain, and it will not mean that until the trial reports and a regulator agrees. Vendor copy that lists these conditions as things the compound is "used for" has quietly converted a list of open questions into a list of claims. Under our own method none of these indications rises above Tier B, and several are unreported.

The case for cure

It is worth stating plainly, because a site that is sceptical about vendors can easily be misread as sceptical about the drugs. The efficacy data here is exceptional by the standards of obesity medicine, where the previous generation of drugs delivered single digit percentage weight loss and several were withdrawn for safety.

Retatrutide, TRIUMPH-1

Lilly's pivotal Phase 3 trial randomised 2,339 adults with obesity and without diabetes to 4 mg, 9 mg, 12 mg or placebo. At 80 weeks, mean weight loss was 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg, against 2.2% on placebo. In a prespecified extension running to 104 weeks in participants with a BMI of 35 or above, mean loss on 12 mg reached 30.3%, and 65.3% of that group ended below a BMI of 30. All three doses met the primary endpoint.

Mean weight change at 80 weeks, TRIUMPH-1

Adults with obesity and without diabetes, n=2,339, randomised to placebo or one of three retatrutide doses.

View as table

Arm	Mean weight change at 80 weeks
Placebo	2.2%
Retatrutide 4 mg	19.0%
Retatrutide 9 mg	25.9%
Retatrutide 12 mg	28.3%

Source: Eli Lilly topline announcement, May 2026. Doses are trial parameters, not guidance.

TRIUMPH-2, in people with obesity and type 2 diabetes, reported 20.8% at 12 mg. TRIUMPH-3, in people with established cardiovascular disease, reported 22.6%.

Semaglutide and tirzepatide

Both are approved on the strength of large randomised programmes, and semaglutide additionally has a cardiovascular outcomes trial behind it showing a reduction in major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease but without diabetes. That result matters more than any weight figure, because it moved these drugs from cosmetic to cardioprotective in the eyes of most regulators and payers.

This is the honest half of the answer. If you are eligible, and you can access the approved product through a prescriber, the evidence supporting that route is stronger than the evidence behind almost anything else in the category.

The case for curse

There are two separate arguments here and they should not be blurred together. One is about the drugs. The other is about how people buy them.

What the drugs themselves do

Gastrointestinal adverse events are common and dose dependent. In TRIUMPH-1 at the 12 mg dose, nausea affected 42.4% of participants against 14.8% on placebo, diarrhoea 32.0% against 13.5%, and vomiting 25.3% against 4.8%. Dysesthesia, an abnormal skin sensation, appeared in 12.5% against 0.9%. Study discontinuation rose with dose, from 4.1% at 4 mg to 11.3% at 12 mg, against 4.9% on placebo.

Adverse events, retatrutide 12 mg against placebo

Participants reporting each event in TRIUMPH-1. The efficacy above and the side effects here come from the same trial, at the same dose.

Retatrutide 12 mg Placebo

View as table

Event	Retatrutide 12 mg	Placebo
Nausea	42.4%	14.8%
Diarrhoea	32.0%	13.5%
Vomiting	25.3%	4.8%
Dysesthesia	12.5%	0.9%
Discontinued the study	11.3%	4.9%

Source: Eli Lilly topline announcement, May 2026.

The weight comes back. In the STEP 1 extension, participants who stopped semaglutide regained roughly two thirds of the weight they had lost within a year. In SURMOUNT-4, after a 36 week tirzepatide run in producing 20.9% mean loss, participants switched to placebo regained about 14% of baseline body weight while those who stayed on treatment lost a further 5.5%. These behave like maintenance therapies, not courses, and anyone budgeting for a finite "cycle" is planning against the trial evidence.

Some of what is lost is lean tissue. This is an active research question rather than a settled one. Observational work using routine care body composition data has reported greater relative lean body mass loss with tirzepatide than semaglutide, on the order of a 2.0% excess at twelve months, and a higher rate of a defined high risk pattern combining large total loss with substantial lean loss. That finding comes from a preprint that has not completed peer review, which under our own method caps it at Tier C, and we are flagging it as suggestive rather than established.

What the grey market does

This is where the word curse earns its place, and it has nothing to do with receptor pharmacology.

Approved GLP-1 products arrive in a metered pen, sterile, endotoxin tested, dose controlled, manufactured under a regulatory quality system, and attached to a pharmacovigilance and recall mechanism. Research grade material arrives as a lyophilised powder in a vial, typically tested for HPLC purity and mass and nothing else, to be reconstituted and measured by the buyer.

The consequences are documented rather than theoretical. Regulators have repeatedly warned about unapproved and compounded GLP-1 products, including counterfeit product, labelling that named pharmacies which had not made the material or did not exist, and dosing errors of up to tenfold arising from drawing doses out of multidose vials rather than using a metered pen. Adverse event reports associated with compounded semaglutide and tirzepatide now run into the hundreds each. Poison centre contacts involving this drug class have risen sharply since 2019, and the overwhelming majority are therapeutic errors, principally double dosing and doses taken too close together, rather than deliberate misuse.

Note what that list does not contain. Almost none of it is the molecule behaving badly. It is packaging, measurement, labelling and provenance. Those are exactly the failure modes that a properly documented supply chain exists to prevent, and exactly the ones a research chemical channel is not built to prevent.

Is research grade the same as the approved drug?

This is the question the whole category turns on, and it deserves a direct answer rather than a hedge.

It may well contain the same molecule. It is not the same product.

A certificate of analysis showing 99% purity by HPLC and a matching mass spectrum tells you that a sample of powder, at the moment it was tested, was predominantly one substance and that the substance had the right molecular weight. That is genuinely useful information and it is more than most vendors offer. Here is the full list of things it does not tell you.

The net peptide content row is the one that quietly matters most for a GLP-1, and we have written about it at length in our guide to reading a certificate of analysis. HPLC purity is an area percentage, not a mass. Lyophilised peptide powder also contains counterions, bound water and residual salts, and net peptide content commonly runs well below the gross weight on the label. A vial sold as 10 mg at 99% purity may hold appreciably less than 10 mg of peptide. For a compound where the trials distinguish carefully between 4 mg, 9 mg and 12 mg, an unstated content figure is not a technicality.

If you are going to evaluate a vendor anyway

People buy these products. Telling them not to has not worked and is not our job. What we can do is make the documentation legible, because the difference between a vendor who publishes real batch data and one who publishes a picture of a chromatogram is the largest single quality signal available to a buyer.

• The certificate is batch specific and its lot number matches the vial you received.
• Both HPLC purity and mass spectrometry are present, not one alone.
• Purity is a measured result, not a specification such as "not less than 98%".
• A peak integration table accompanies the chromatogram, with retention times and area percentages.
• The analytical method is stated in enough detail to be repeated.
• Net peptide content is given, or its absence is acknowledged rather than hidden.
• A testing laboratory is named, with its own report number and signatory.
• Endotoxin and sterility results are present, or their absence is stated plainly as a limitation.
• The compound is what it claims to be, checked against the stated molecular formula.

A vendor who clears all nine is documenting properly. That is a real and meaningful distinction between suppliers, and it is the distinction this site exists to draw. It is still not the same thing as an approved medicine, and no amount of paperwork converts one into the other.

Common questions

Compound by compound

This page argues about the category. Each compound also has its own guide with its regulatory status, trial data, discontinuation evidence and the myths attached to it: semaglutide, tirzepatide and retatrutide, alongside the rest of the set.

The verdict

On the evidence, these are the most effective pharmacological treatments for obesity yet developed, and the cardiovascular outcome data means they are no longer reasonably described as vanity drugs. Calling the class a curse on the pharmacology alone is not supportable.

The curse is real, but it is located somewhere more specific than most coverage admits. It sits in the gap between a molecule and a medicine: sterility, endotoxin, dose accuracy, cold chain, provenance, recall, and the ability of a buyer to verify any of it. The approved products close that gap. A research chemical vial does not, and a certificate of analysis narrows it without closing it.

Retatrutide is the sharpest illustration. It will very likely be approved. Its Phase 3 results are the strongest in the field. And right now it is an unapproved compound with no lawful compounding route, being sold in vials to people who will reconstitute it on a kitchen counter, roughly a year and a half before any regulator is expected to have finished reading the dossier. Both of those things are true at once, and the second one is not cancelled by the first.

Sources

• Eli Lilly, TRIUMPH-1 topline results, May 2026. Company announcement.
• Eli Lilly, What to know about retatrutide. Manufacturer statement of investigational status.
• TRIUMPH-1 trial registration, NCT05929066.
• Trial counts and indications from the ClinicalTrials.gov registry, queried 5 September 2026.
• US Food and Drug Administration, FDA's concerns with unapproved GLP-1 drugs used for weight loss.
• Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomised studies.
• GLP-1 receptor agonist cases reported to United States poison centers, 2017 to 2022.
• Lean body mass comparison, medRxiv preprint. Not peer reviewed. Cited at Tier C and flagged as suggestive only.

Back to PeptoPurity